Avandia Class Action Litigation
Case Overview
Plaintiffs, J.B. Hunt Transport Services, Inc. and Group Health, Life and Disability Plan of J.B. Hunt Transport Services, Inc. and UFCW Local 1776 and Participating Employers Health and Welfare Fund (collectively, the “Third Party Payor Plaintiffs” or “TPPs”) seek to hold GlaxoSmithKline (“GSK”) accountable for misleading consumers with type-2 diabetes that their drug Avandia lowered cardiovascular risk when in fact it increased it. TPP Plaintiffs paid for part or all of its participants purchases of the prescription drugs Avandia, Avandamet, and/or Avandaryl (“Avandia Drugs”).
To increase the sales of Avandia, GSK embarked on a comprehensive and carefully-orchestrated scheme to promote Avandia’s safety, efficacy and effectiveness through a fraudulent and deceptive marketing program. In addition to the thousands of people who died or suffered serious injury as a result of their use of Avandia, third-party payors such as Plaintiffs who paid for the drug, also fell victim to GSK’s wrongful scheme to promote and market the Avandia Drugs.
Keller Rohrback is part of the team prosecuting these claims against GSK on behalf of the TPPs, who have brought RICO claims on behalf of the following class:
All entities in the United States of America and its territories, which indirectly purchased, and/or provided reimbursement for some or all of the purchase price for the drugs Avandia, Avandamet, and/or Avandaryl from May 25, 1999 until August 14, 2007.
Practice Areas
